Clinical Trials · NCT01749137

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Name: Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Setmelanotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 74
Start date: Jan 2013
Locations: 6 sites, United States
Primary endpoint: Percent Change From Baseline in Body Weight

View Setmelanotide compound reference